Tumor Response on CT following hypofractionated stereotactic ablative body radiotherapy for small hypervascular hepatocellular carcinoma with cirrhosis

Naoko Sanuki, Atsuya Takeda, Tomikazu Mizuno, Yohei Oku, Takahisa Eriguchi, Shogo Iwabuchi, Etsuo Kunieda

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

OBJECTIVE. The purpose of this study is to evaluate the CT appearances of tumor responses following hypofractionated stereotactic ablative body radiotherapy for small hypervascular hepatocellular carcinomas (HCCs) and to assess the relationship between tumor responses and local control. MATERIALS AND METHODS. Among 277 HCC tumors treated with stereotactic ablative body radiotherapy (35 or 40 Gy per five fractions), we selected enhanced lesions on arterial phase CT performed before stereotactic ablative body radiotherapy. Radiographic findings after stereotactic ablative body radiotherapy were evaluated during a 2-year followup period with the modified Response Evaluation Criteria in Solid Tumors. Local control and survival rates were calculated with the Kaplan-Meier method. RESULTS. Forty-two tumors with a median size of 2.1 cm (range, 1.0-3.8 cm) were selected with a median follow-up of 23.3 months (range, 9-56 months). Local recurrence was observed in two tumors after achieving a complete response (CR). The 2-year local control rate was 97%, and the overall survival rate was 81%. CR increased from 10 (24%) to 28 (67%) to 30 (71%) tumors at 3, 6, and 12 months after stereotactic ablative body radiotherapy. Overall CR at maximum follow-up was 39 tumors (93%), yet three enhanced tumors persisted for more than 2 years. The median time to achieve CR was 5.9 months (range, 1.2-34.2 months). CONCLUSION. The CR rate in hypervascular HCCs after hypofractionated stereotactic ablative body radiotherapy increased during the 2-year follow-up period. Cautious and continuous observation until tumor regrowth is considered relevant to evaluate a true effect of this treatment. Further studies for the optimal evaluation of treatment outcome after stereotactic ablative body radiotherapy are warranted.

Original languageEnglish
JournalAmerican Journal of Roentgenology
Volume201
Issue number6
DOIs
Publication statusPublished - 2013 Dec
Externally publishedYes

Fingerprint

Radiosurgery
Hepatocellular Carcinoma
Fibrosis
Neoplasms
Observation
Recurrence

Keywords

  • Hepatocellular carcinoma
  • Modified response evaluation criteria in solid tumors
  • Stereotactic ablative body radiotherapy
  • Tumor marker

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Tumor Response on CT following hypofractionated stereotactic ablative body radiotherapy for small hypervascular hepatocellular carcinoma with cirrhosis. / Sanuki, Naoko; Takeda, Atsuya; Mizuno, Tomikazu; Oku, Yohei; Eriguchi, Takahisa; Iwabuchi, Shogo; Kunieda, Etsuo.

In: American Journal of Roentgenology, Vol. 201, No. 6, 12.2013.

Research output: Contribution to journalArticle

Sanuki, Naoko ; Takeda, Atsuya ; Mizuno, Tomikazu ; Oku, Yohei ; Eriguchi, Takahisa ; Iwabuchi, Shogo ; Kunieda, Etsuo. / Tumor Response on CT following hypofractionated stereotactic ablative body radiotherapy for small hypervascular hepatocellular carcinoma with cirrhosis. In: American Journal of Roentgenology. 2013 ; Vol. 201, No. 6.
@article{e4bb44518f6448ef9cd80098f08620be,
title = "Tumor Response on CT following hypofractionated stereotactic ablative body radiotherapy for small hypervascular hepatocellular carcinoma with cirrhosis",
abstract = "OBJECTIVE. The purpose of this study is to evaluate the CT appearances of tumor responses following hypofractionated stereotactic ablative body radiotherapy for small hypervascular hepatocellular carcinomas (HCCs) and to assess the relationship between tumor responses and local control. MATERIALS AND METHODS. Among 277 HCC tumors treated with stereotactic ablative body radiotherapy (35 or 40 Gy per five fractions), we selected enhanced lesions on arterial phase CT performed before stereotactic ablative body radiotherapy. Radiographic findings after stereotactic ablative body radiotherapy were evaluated during a 2-year followup period with the modified Response Evaluation Criteria in Solid Tumors. Local control and survival rates were calculated with the Kaplan-Meier method. RESULTS. Forty-two tumors with a median size of 2.1 cm (range, 1.0-3.8 cm) were selected with a median follow-up of 23.3 months (range, 9-56 months). Local recurrence was observed in two tumors after achieving a complete response (CR). The 2-year local control rate was 97{\%}, and the overall survival rate was 81{\%}. CR increased from 10 (24{\%}) to 28 (67{\%}) to 30 (71{\%}) tumors at 3, 6, and 12 months after stereotactic ablative body radiotherapy. Overall CR at maximum follow-up was 39 tumors (93{\%}), yet three enhanced tumors persisted for more than 2 years. The median time to achieve CR was 5.9 months (range, 1.2-34.2 months). CONCLUSION. The CR rate in hypervascular HCCs after hypofractionated stereotactic ablative body radiotherapy increased during the 2-year follow-up period. Cautious and continuous observation until tumor regrowth is considered relevant to evaluate a true effect of this treatment. Further studies for the optimal evaluation of treatment outcome after stereotactic ablative body radiotherapy are warranted.",
keywords = "Hepatocellular carcinoma, Modified response evaluation criteria in solid tumors, Stereotactic ablative body radiotherapy, Tumor marker",
author = "Naoko Sanuki and Atsuya Takeda and Tomikazu Mizuno and Yohei Oku and Takahisa Eriguchi and Shogo Iwabuchi and Etsuo Kunieda",
year = "2013",
month = "12",
doi = "10.2214/AJR.12.10169",
language = "English",
volume = "201",
journal = "American Journal of Roentgenology",
issn = "0361-803X",
publisher = "American Roentgen Ray Society",
number = "6",

}

TY - JOUR

T1 - Tumor Response on CT following hypofractionated stereotactic ablative body radiotherapy for small hypervascular hepatocellular carcinoma with cirrhosis

AU - Sanuki, Naoko

AU - Takeda, Atsuya

AU - Mizuno, Tomikazu

AU - Oku, Yohei

AU - Eriguchi, Takahisa

AU - Iwabuchi, Shogo

AU - Kunieda, Etsuo

PY - 2013/12

Y1 - 2013/12

N2 - OBJECTIVE. The purpose of this study is to evaluate the CT appearances of tumor responses following hypofractionated stereotactic ablative body radiotherapy for small hypervascular hepatocellular carcinomas (HCCs) and to assess the relationship between tumor responses and local control. MATERIALS AND METHODS. Among 277 HCC tumors treated with stereotactic ablative body radiotherapy (35 or 40 Gy per five fractions), we selected enhanced lesions on arterial phase CT performed before stereotactic ablative body radiotherapy. Radiographic findings after stereotactic ablative body radiotherapy were evaluated during a 2-year followup period with the modified Response Evaluation Criteria in Solid Tumors. Local control and survival rates were calculated with the Kaplan-Meier method. RESULTS. Forty-two tumors with a median size of 2.1 cm (range, 1.0-3.8 cm) were selected with a median follow-up of 23.3 months (range, 9-56 months). Local recurrence was observed in two tumors after achieving a complete response (CR). The 2-year local control rate was 97%, and the overall survival rate was 81%. CR increased from 10 (24%) to 28 (67%) to 30 (71%) tumors at 3, 6, and 12 months after stereotactic ablative body radiotherapy. Overall CR at maximum follow-up was 39 tumors (93%), yet three enhanced tumors persisted for more than 2 years. The median time to achieve CR was 5.9 months (range, 1.2-34.2 months). CONCLUSION. The CR rate in hypervascular HCCs after hypofractionated stereotactic ablative body radiotherapy increased during the 2-year follow-up period. Cautious and continuous observation until tumor regrowth is considered relevant to evaluate a true effect of this treatment. Further studies for the optimal evaluation of treatment outcome after stereotactic ablative body radiotherapy are warranted.

AB - OBJECTIVE. The purpose of this study is to evaluate the CT appearances of tumor responses following hypofractionated stereotactic ablative body radiotherapy for small hypervascular hepatocellular carcinomas (HCCs) and to assess the relationship between tumor responses and local control. MATERIALS AND METHODS. Among 277 HCC tumors treated with stereotactic ablative body radiotherapy (35 or 40 Gy per five fractions), we selected enhanced lesions on arterial phase CT performed before stereotactic ablative body radiotherapy. Radiographic findings after stereotactic ablative body radiotherapy were evaluated during a 2-year followup period with the modified Response Evaluation Criteria in Solid Tumors. Local control and survival rates were calculated with the Kaplan-Meier method. RESULTS. Forty-two tumors with a median size of 2.1 cm (range, 1.0-3.8 cm) were selected with a median follow-up of 23.3 months (range, 9-56 months). Local recurrence was observed in two tumors after achieving a complete response (CR). The 2-year local control rate was 97%, and the overall survival rate was 81%. CR increased from 10 (24%) to 28 (67%) to 30 (71%) tumors at 3, 6, and 12 months after stereotactic ablative body radiotherapy. Overall CR at maximum follow-up was 39 tumors (93%), yet three enhanced tumors persisted for more than 2 years. The median time to achieve CR was 5.9 months (range, 1.2-34.2 months). CONCLUSION. The CR rate in hypervascular HCCs after hypofractionated stereotactic ablative body radiotherapy increased during the 2-year follow-up period. Cautious and continuous observation until tumor regrowth is considered relevant to evaluate a true effect of this treatment. Further studies for the optimal evaluation of treatment outcome after stereotactic ablative body radiotherapy are warranted.

KW - Hepatocellular carcinoma

KW - Modified response evaluation criteria in solid tumors

KW - Stereotactic ablative body radiotherapy

KW - Tumor marker

UR - http://www.scopus.com/inward/record.url?scp=84888330280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888330280&partnerID=8YFLogxK

U2 - 10.2214/AJR.12.10169

DO - 10.2214/AJR.12.10169

M3 - Article

VL - 201

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

SN - 0361-803X

IS - 6

ER -